What's Happening?
Incyte has announced the 24-week results from its Phase 3 TRuE-AD4 trial, evaluating the efficacy and safety of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis. The study, presented at the 2026 European Academy of Dermatology and Venereology
Symposium, showed that 84.3% of patients achieved a 75% improvement in the Eczema Area and Severity Index (EASI75) and 70.6% achieved Investigator's Global Assessment Treatment Success (IGA-TS) at Week 24. The cream was well-tolerated, with few adverse events reported. These results support a Type-II variation application for the cream's use in the European Union, with feedback expected in the first half of 2026.
Why It's Important?
The positive long-term data for Opzelura cream is significant as it reinforces the treatment's potential as a nonsteroidal option for adults with moderate atopic dermatitis who have not responded well to other therapies. This could provide a new avenue for patients seeking alternatives to traditional treatments like corticosteroids. The results also bolster Incyte's position in the dermatology market, potentially leading to increased adoption of Opzelura in both the U.S. and Europe. The successful trial outcomes may influence regulatory decisions and expand the cream's market reach, benefiting patients and healthcare providers.
What's Next?
Incyte plans to continue working with European regulatory authorities to secure approval for Opzelura in the EU. The company is also likely to focus on further clinical trials to explore additional indications and expand the cream's use. As the regulatory process unfolds, Incyte will need to address any feedback from authorities and prepare for potential market entry in Europe. The company's ongoing investment in research and development will be crucial in maintaining its competitive edge and meeting the needs of patients with atopic dermatitis.
